C-NBUCaging biology, mTORC1 inhibition, AMPK activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Advance next-generation selective mTORC1 inhibitors intended to improve intrinsic capacity in older people.
Platform for next-generation selective mTORC1 inhibitor drug assets, supported by ARPA-H PROSPR funding.
Awarded up to $30.8 million through ARPA-H's PROSPR Program to advance the TORnado platform.
Define best practices for collecting biomarker data in geroscience and longevity biotechnology clinical trials to support participant stratification, intervention prioritization, response monitoring, reuse of clinical data, and broader biomarker validation.
Publication-based recommendations for standardizing biomarker data collection in clinical trials by longevity biotechnology companies.
Published recommendations in npj Aging in 2025.
The publication proposes standardized biomarker collection practices intended to improve data quality and enable pre-competitive benchmarking and validation of aging biomarkers.
Define recommended practices for collecting biomarker data in clinical trials by longevity biotechnology companies so aging biomarkers can support participant stratification, intervention prioritization, response monitoring, validation, benchmarking, and future data reuse.
Pre-competitive recommendations for biomarker data collection and application in geroscience clinical trials.
Publication of recommendations in npj aging.
The publication proposes that broad adoption of standardized biomarker collection practices would improve clinical trial data quality and benefit geroscience through reusable clinical datasets.
Define recommended practices for collecting biomarker data in clinical trials run by longevity biotechnology companies.
Publication proposing standardized biomarker data collection practices for stratifying participants, prioritizing interventions, monitoring responses to geroprotectors, and supporting reuse of clinical data.
Published recommendations in npj Aging in 2025.
The publication argues that broad adoption of standardized biomarker collection practices would improve clinical trial data quality and support geroscience biomarker validation and benchmarking.
Develop therapeutics targeting age-related metabolic decline through AMPK and mitochondrial activation pathways.
Clinical-stage drug program associated with Amplifier Therapeutics, a Cambrian Bio pipeline company; Phase 1b clinical trial dosing in patients.
Amplifier Therapeutics dosed first patients in a Phase 1b clinical trial and expanded its Series A financing to $33.25 million.
Build and advance multiple therapeutics that target biological drivers of aging, with the goal of treating or preventing age-related chronic diseases and lengthening healthspan.
Distributed drug-development model partnering with scientists and advancing multiple therapeutic programs against mechanisms of aging.
Cambrian BioPharma closed a $100 million Series C to advance healthspan-boosting therapeutics toward the clinic.
Advance a novel mTORC1-selective inhibitor intended to improve intrinsic capacity in older people and address aging-related decline.
Therapeutic intervention targeting mTORC1 signaling through selective inhibition.
Awarded up to $30.8 million from ARPA-H's PROSPR program to advance the program.
Develop therapeutics in women's health under a Cambrian pipeline-company program.
Exclusive license with Massachusetts General Hospital and seed-funded biotech development program.
Oviva announced $11.5 million in seed financing and an exclusive license with MGH; later public material says Granata Bio acquired Oviva Therapeutics from Cambrian Bio.
Develop therapeutics for women's health through Oviva Therapeutics, a Cambrian Bio pipeline company.
Exclusive license with Massachusetts General Hospital and seed-financed therapeutic development program.
Oviva announced $11.5 million in seed financing and an exclusive license with MGH; later acquired by Granata Bio from Cambrian Bio.
Develop cell therapies for neuromuscular diseases and cancers through Vita Therapeutics, a Cambrian Bio pipeline company.
Cell therapy development program supported by Series B financing.
Vita Therapeutics closed a $31 million Series B financing to develop cell therapies for neuromuscular diseases and cancers.